Theses (Faculty of Medicine)
Állandó link (URI) ehhez a gyűjteményhez
Böngészés
legfrissebb feltöltések
Megjelenítve 1 - 20 (Összesen 1439)
Tétel Korlátozottan hozzáférhető COVID 19 disease and vaccination statusBaiden, Phoebe; Székely , András; Általános Orvostudományi Kar::Orvosi Képalkotó Intézet::Radiológiai Tanszék; DE--Általános Orvostudományi Kar; Tresó , Anita; Béresová , Monika; Általános Orvostudományi Kar::Orvosi Képalkotó Intézet::Radiológiai Tanszék; Általános Orvostudományi Kar::Orvosi Képalkotó IntézetA three-wave pattern of reported cases affected several countries around the world. The first wave happened in the spring of 2020. The second wave occurred at the end of summer 2020 and fall 2020. The third wave occurred at the start of 2021Tétel Korlátozottan hozzáférhető ROLE OF IMMUNOTHERAPY IN CARDIOVASCULAR DISEASESMaklai, Ahmed; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Dóra; Szentmiklósi, József; Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetAtherosclerosis, an inflammatory, lipid-driven disease of the arteries, is the primary cause of the majority of CVD problems, including CAD, MI, PAD, aneurysms, and strokes. The only medicine now available to treat cardiovascular disease caused by atherosclerosis is anti-IL-1 antibody therapy (canakinumab). Interleukin-1 actively promotes atherosclerosis. Along with activating macrophages, IL-1 also induces the activation of vascular smooth muscle cells, endothelial cells, and endothelial cells. Moreover, it boosts IL-6 synthesis, a pro-inflammatory cytokine that stimulates the creation and release by hepatocytes of a number of acute phase reactants, including C-reactive protein. Anti-IL-1 therapy improved primary and secondary cardiovascular disease outcomes and decreased infection risk, but it did not lower overall mortality. This has led to the development of novel, effective immunotherapeutics. Effective targets include chemokines and their receptors, immunological checkpoints, immune cell metabolism, hormones, and lipid mediators. These state-of-the-art immunotherapeutics are expected to improve primary and secondary cardiovascular disease endpoints while lowering cardiovascular disease mortality without immune-suppressive side effects. Because the pathogenesis of pericarditis involves immunological pathways, immunotherapy drugs like Rilonacept, a soluble decoy receptor that binds to IL-1 alpha or beta with higher affinity than cell surface receptors, can also be utilized to treat this condition. Immunotherapy is a treatment option for cancer. HER-2-targeted treatments, CTLA-blockade, and PD/PDL-1 inhibitor therapy are the main pharmacological classes; nevertheless, all of them are linked to significant cardiac damage, which can range from mild to severe in some situations.Tétel Korlátozottan hozzáférhető The Efficacy of Low Dose Computed Tomography to Diagnose Pathologies in the General, Asymptomatic PopulationOkewulonu, Onyinyechi; Székely, András; Általános Orvostudományi Kar::Orvosi Képalkotó Intézet::Radiológiai Tanszék; DE--Általános Orvostudományi Kar; Treso, Anita; Béres, Mónika; Általános Orvostudományi Kar::Orvosi Képalkotó Intézet::Radiológiai Tanszék; Általános Orvostudományi Kar::Orvosi Képalkotó IntézetThe aim of this study is to ascertain how effective Low Dose Computed Tomography of the chest is to diagnose potentially serious pathologies in asymptomatic people who do not quite fit into official screening criteria.Studies show that mortality rates could be reduced by early diagnosis and management. The CT scans of over 150 patients from November 12th, 2020 to 4th of April, 2021 were analysed in this study. It was an open study with no patients excluded regardless of age or smoking status.Of the 152 CT scans analysed 73 were positive for a pathology. 23 scans showed signs of Emphysema. 23 scans showed signs of nodules or foci in the lung. 8 scans showed signs of COVID-19 pneumonia,37 scans showed signs of Atherosclerosis,2 scans had signs of Hiatal Hernia.Tétel Korlátozottan hozzáférhető pharmacology of drugs which improve insulin resistancepatel, mohammed; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Drimba, László; Megyeri, Attila; Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetAs the epidemiology of type 2 diabetes continues to rise exponentially, we take time to understand the multistep process by which the disease starts, progresses and worsens aswell as taking a look at the pharmacology of medication used to treat insulin resistance as this propagates the disease.Tétel Korlátozottan hozzáférhető Pharmacological Treatment Options in Long QT SyndromeSandrouni, Karin; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Drimba, Laszló; Megyeri, Attila; Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetThe long QT syndrome (LQTS) is one of the first identified and most studied channelopathies where genetics can play a role in inheritance of abnormal prolongation of ventricular repolarization predisposing these given individuals to life threatening ventricular arrhythmias and sudden cardiac death. This QT prolongation can also be brought forth in an acquired manner (relating to use of certain medications, electrolyte disturbances or certain cardiac diseases). We explore the the current available pharmacotherapeutic options for the treatment of LQTS and emphasize their use as first line agents while mentioning other non-pharmacological interventions that we sometimes resort to. We delve into the molecular genetics, clinical features, genotype-phenotype correlations and genotype-specific approaches in treatment and mention some of the pharmacological treatment options that have promising features for use in the future .Tétel Korlátozottan hozzáférhető New therapeutic methods in the treatments of ulcerative colitisKondo, Teru; Porszász , Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József; Halasi, Barbara Dóra; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetUlcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum, typically diagnosed around ages 30-40 with equal incidence in men and women. Its multifactorial pathogenesis involves environmental triggers, immune dysfunction, and potential microbial imbalance in genetically predisposed individuals. UC management is primarily aimed at symptom control, as the disease lacks curative treatments aside from colectomy, with therapies often required lifelong due to its chronic nature. Patients experience alternating periods of remission and exacerbations, sometimes necessitating intensified treatment or hospitalization, and in severe cases, surgical intervention. Historically reliant on corticosteroids, UC treatment has evolved rapidly with the advent of small molecule and biologic therapies, offering alternatives to manage symptoms effectively. Following the success of anti-tumor necrosis factor α (anti-TNFα) biologics, subsequent therapeutic developments have targeted various immune pathways including adhesion molecules, cytokines (IL-12/23, TL1A, IL-36), Janus kinase (JAK), and phosphodiesterase. Despite the transformative impact of these therapies, many patients still require alternative options due to adverse effects or treatment failure, driving the development of novel agents with improved safety profiles and efficacy. Emerging strategies also focus on modulating less-targeted immune cells (B cells, innate lymphoid cells), addressing fibrosis, regulating the gut-brain axis, and optimizing host-microbiome interactions, promising innovative approaches for future UC management. Ongoing translational research underscores the potential of these advancements, providing a comprehensive outlook on current and forthcoming IBD therapeutics.Tétel Korlátozottan hozzáférhető New advances in the pharmacological management of HFrEF patientsToshiya, Tanaka; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Megyeri, Attila; Drimba, László; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás TanszékThis thesis emphasizes the high mortality and morbidity of HF, thus importance of pharmacotherapy is described. Then I give a description on etiology, risk factor and incidence of HF. In the following chapters I explain pathomechanism of HF for better understanding. It is necessary to decide the way of treatment, I demonstrate the main diagnostic and screening criteria of HF. Finally, I describe pharmacotherapy of HF in detail.Tétel Korlátozottan hozzáférhető Modern therapeutic approach to hyperlipidemia treatmentStrul, Leeann; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Megyeri, Attila; Drimba, László; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás TanszékThis thesis covers different approaches used in hyperlipidemia and the most common lipids lowering drugs that are used nowadays, their mechanism of action, route of administration and adverse effects together with the newest drugs available for lowering the lipid levels.Tétel Korlátozottan hozzáférhető New advances in Duchenne muscular dystrophyAnanyan, Edgar; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József; Halasi, Barbara Dóra; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetDuchenne muscular dystrophy (DMD) is a progressive, debilitating disorder that results from a mutation present on the X chromosome, leading to the inability to produce functional dystrophin protein. Progressive tissue damage accumulates with every muscle contraction, caused by the lack of dystrophin, and leads to loss of muscle strength, chronic inflammation, and fibrosis. Current treatment involves administration of corticosteroids and management of cardiac and respiratory symptoms as the disease progresses. However, current treatment only slows down the progression of the disease with significant side effects. Therefore multiple new drugs are undergoing trials to either slow down the symptom progression or treat the underlying cause of the disease. In this thesis, we aim to discuss the efficacy, mode of action, and tolerability of newly emerging treatments that could potentially benefit DMD patients.Tétel Korlátozottan hozzáférhető Complex pharmacological management of Acute Myocardial InfarctionKato, Kiichi; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József; Halasi, Barbara; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetThe pharmacotherapy for acute myocardial infarction (AMI) involves a combination of established and evolving treatments. Oxygen, nitroglycerin, aspirin, and occasionally morphine form the fundamental therapy, aimed at addressing the primary cause of coronary atherosclerotic thrombus. Early administration of cardioprotective drugs like beta-blockers is crucial due to their proven benefits in reducing myocardial oxygen demand and mortality. While ACE inhibitors have demonstrated benefits in chronic conditions, their routine use in the emergency department for AMI is not always necessary. Heparin, including both unfractionated heparin (UFH) and low molecular weight heparins (LMWHs), plays a well-defined role in preventing further thrombus formation. Additionally, glycoprotein IIb/IIIa inhibitors are emerging as valuable additions to the pharmacological toolkit, particularly in high-risk patients or those undergoing percutaneous coronary intervention (PCI).Tétel Korlátozottan hozzáférhető New advances in the DMARDs therapySaito, Mizuki; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dóra; Szentmiklósi, József; Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetThis thesis is about the history of medications against rheumatoid arthritis and the new DMARDs currently under development. A major turning point in the history of pharmacological treatment against rheumatoid arthritis was the development and use of methotrexate.Unlike previous symptomatic drugs, methotrexate acts directly on the pathophysiology of rheumatoid arthritis, resulting in a significant improvement in the prognosis of many patients of rheumatoid arthritis. Further developments, such as targeted DMARDs containing Jak inhibitors and biological DMARDs such as IL-6 inhibitors and anti-TNFs, have enabled patients who could not achieve remission with methotrexate alone to achieve remission. In addition, new drugs targeting completely different steps of the pathomechanism from previously developed DMARDs are currently under development. While drugs for existing and new targets are being developed, another aspect of advance is the development of biosimilars which make treatments available at a lower cost. As a conclusion, many of new DMARDs are currently under development, and it is hoped that further advances of the developments will relieve more patients from suffering from rheumatoid arthritis in the future.Tétel Korlátozottan hozzáférhető Pharmacology of antimalarial drugsSade, Shachar; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Megyeri, Attila; Drimba, László; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás TanszékMalaria remains one of the most significant infectious diseases worldwide, with a devastating impact on public health, particularly in regions with limited resources. The pharmacology of antimalarial drugs is a crucial aspect of malaria control strategies, encompassing the understanding of drug mechanisms, pharmacokinetics, pharmacodynamics, resistance patterns, and adverse effects. This work comprehensively examines the pharmacological aspects of antimalarial drugs, covering some of the major drugs belonging to the classes such as quinolines, artemisinin derivatives, antifolates, and antimicrobials. Also included are the most notable combinations in the treatment of malaria. Additionally exploration of the complex mechanisms of action employed by these drugs to combat the Plasmodium parasites is covered. While antimalarial drugs play a vital role in malaria control and elimination efforts, challenges persist, including the spread of drug-resistant parasites, limited access to treatment in endemic regions, and gaps in healthcare infrastructure. A foundational understanding of the pharmacology of antimalarial drugs is essential for medical students, healthcare workers and physicians to effectively manage malaria cases, advocate for public health interventions, and contribute to malaria eradication efforts worldwide.Tétel Korlátozottan hozzáférhető New Therapy for Management of Heart FailureOse, Haruka; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dóra; Megyeri, Attila; Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetThe article outlines treatments for different types of heart failure: HFrEF, HFmrEF, and HFpEF. Medications like ACE inhibitors, MRAs, beta-blockers, and ARNI are recommended for HFrEF, while HFmrEF patients may benefit from treatments used for HFrEF. However, effective medications for HFpEF are lacking. New drugs such as SGLT2 inhibitors, omecamtiv mecarbil, and vericiguat show promise for HFrEF. ARNI, notably effective in reducing exacerbations and mortality, is expected to become a cornerstone treatment. Additionally, drugs like ivabradine and SGLT2 inhibitors offer added benefits, contributing to the evolving landscape of heart failure management. There needs further research and trials to further increase survival rate of heart failure patients.Tétel Korlátozottan hozzáférhető Chronological development of the skin immune barrier in different regionsTirosh, Noam; Dajnoki, Zsolt; Általános Orvostudományi Kar::Bőrgyógyászati Tanszék; DE--Általános Orvostudományi Kar; Beke, Gabriella; Dull, Katalin; Általános Orvostudományi Kar::Bőrgyógyászati Tanszék; Általános Orvostudományi Kar::Immunológiai IntézetOur skin is not uniform; besides anatomical and physiological differences, the chemical milieu and microbiota also vary among different skin regions. In addition, our research group has identified a distinct immunological milieu, with increased immunological tuning characterizing the sebaceous gland-rich, sebaceous skin regions compared to the gland-poor, dry areas. However, the onset of the development of these immunotopographical differences is currently unknown. We hypothesize that before puberty, our skin is uniform, and region-specific characteristics only emerge during adolescence due to hormonal changes. To prove this, we aimed to investigate topographically different skin areas derived from healthy children and adults. We performed TaqMan low-density array (TLDA) and examined the gene expression levels of several cytokines, TFs, chemokines, AMPs, and transcription factors in the sebaceous (sebaceous gland-rich [SGR)) and dry (gland-poor [GP]) skin regions of healthy children (0-10 years) and adults (18 years and above) (n=8-8). We did not find significant differences in the examined molecules between the skin regions of children, while, in adulthood, both the dry and sebaceous skin regions exhibited increased immune activity, however, this increase was much more pronounced in the sebaceous skin region with significantly higher expression of IL-17 signaling mediators (e.g. IL-17, IL-1β, lipocalin, S100A family members). Since the most prominent differences were found in the components of IL-17 signaling, we also detected and quantified the source of the IL-17 cytokine in these skin specimens by double immunofluorescence staining at the protein level. Our results suggest that the predominant source of IL-17 is non-pathogenic Th17 cells in all sample types, and Th17 cell count is substantially and significantly increased in the sebaceous skin region of adults. Our findings indicate that the differences detectable between different skin regions in adults are not present in the skin of children, and the topographic immunological differences develop after adolescence.Tétel Korlátozottan hozzáférhető Pharmacological treatment of GoutBar On, Dana; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Drimba, László; Megyeri, Attila; Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetGout is a chronic intermittent arthritis that is becoming increasingly prevalent around the world. Gout is caused by the deposition of Monosodium Urate crystals in articular and extra articular locations. Hyperuricemia is the main precondition for this phenomenon. Gout attacks are characterized by pain and swelling. This paper will cover the epidemiology, the pathophysiology, the diagnosis and the clinical presentations of Gout, and mainly the 2 different pharmaceutical goals of Gout treatment. The first goal of Gout treatment is to mitigate acute attacks by using various anti-inflammatory medications such as NSAIDs, Corticosteroids, Colchicine and anti-IL-1β biological therapy. The second aim of treatment is to lower urate levels in serum by using medications such as Xanthine Oxidase inhibitors, Uricosuric agents and Uricase replacements. Although the current treatment options are effective, research into biological and immuno-therapy options offer glimpses of future improvement in Gout treatment and its underlying causes.Tétel Korlátozottan hozzáférhető Management of Diabetic ComplicationsKevu, Ejiroghene; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Drimba, László; Megyeri, Attila; Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetDiabetes mellitus is a chronic metabolic disorder that is characterized by hyperglycemia. This unchecked chronic hyperglycemia can give rise to a myriad of complications including blindness, myocardial infarction and renal failure. These complications, left untreated, can lead to significant morbidity and mortality. This thesis reviews the etiology, pathogenesis and treatment modalities for the chronic complications of T2DM with special emphasis on the microvascular and macrovascular complications. The importance of a multidisciplinary approach and lifestyle modifications, glycemic control, pharmacologic and surgical intervention in the management of chronic diabetic complications will be discussed here.Tétel Korlátozottan hozzáférhető Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure ManagementAlswis, Khaled; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József; Halasi, Barbara Dóra; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetHeart failure is a disease with multiple causes but uniform clinical picture. Compromised cardiac activity triggers many compensatory mechanisms, one of which is the renin-angiotensin-aldosterone system, which can lead to negative effects when activated chronically. Modulation of the renin-angiotensin-aldosterone-system is therefore needed in the treatment of heart failure to prevent exacerbation of the disease. Such modulation can be achieved with different classes of drugs, such as ACE-I, ARBs, ARNI, MRA, and renin inhibitors. This modulation of the renin-angiotensin-aldosterone-system has proven to have favourable effects on the mortality and morbidity of heart failure patients, and is therefore a standard treatment.Tétel Korlátozottan hozzáférhető COVID and strokeJesdapipat, Puttaanan; Oláh, László; Általános Orvostudományi Kar::Neurológiai Tanszék; DE--Általános Orvostudományi Kar; Kis, Balázs; Szegedi, István; Általános Orvostudományi Kar::Orvosi Képalkotó Intézet::Radiológiai Tanszék; Általános Orvostudományi Kar::Neurológiai TanszékCoronavirus disease 2019 (COVID-19) is a severe acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First detected in December 2019, the virus has since spread across the globe and has infected 768 million people and has led to over 7 million deaths worldwide. In addition to its classical presentation of upper respiratory tract symptoms, a growing body of evidence had found an association between COVID-19 and a variety of neurological disorders, including cerebrovascular disease. Physicians should be aware of the possibility of neurological deficits due to stroke as an initial presentation of COVID-19, which significantly contributes to morbidity and mortality seen in this population of patients, and this knowledge should prompt timely management to optimize treatment outcome. This thesis reviews the epidemiology, pathophysiology, and management of acute ischemic stroke associated with COVID-19. The risk of acute stroke is significantly increased in severe COVID-19 disease with higher severity and worse prognosis. SARS-CoV-2 may directly or indirectly play a role in stroke pathogenesis through several mechanisms. While management of stroke in COVID-19 patients follows the same treatment protocol as non-COVID patients, there are some special considerations to keep in mind while managing these patients. Further studies are needed to help to understand risk, manifestations, response to treatment strategies, and outcomes in stroke patients with COVID-19 infection.Tétel Korlátozottan hozzáférhető Pathogenesis and Therapy of AcneZiad Saleh Alzubaidi, Joud; Törőcsik, Dániel; Általános Orvostudományi Kar::Bőrgyógyászati Tanszék; DE--Általános Orvostudományi Kar; Várvölgyi, Tnde; Garbóczy , Szabolcs; Általános Orvostudományi Kar::Bőrgyógyászati Tanszék; Általános Orvostudományi Kar::Pszichiátriai TanszékThis thesis summarizes the various factors that contribute to the development of acne, a common dermatological condition that affects millions of people worldwide. Through an in-depth literature review, the role of bacteria, hormones, diet, genetics, hyperkeratinisation and sebum in the onset and severity of acne is detailed. It also focuses on the psychological and social impact of acne, including the negative effects on self-esteem, body image and quality of life. Altogether emphasizing that a complex and adaptive approach addressing both the physical and emotional aspects of acne, including herbal medicines, topical treatments, systemic medications and procedures such as light therapy, lasers and microdermabrasion, are needed not only for the current presence of acne, but also to prevent future recurrences and deal with complications, the most important of which is scarring.Tétel Korlátozottan hozzáférhető Predictors of graft patency following coronary artery bypass graft surgeryShima, Riko; Édes, István; Általános Orvostudományi Kar::Kardiológiai Intézet; DE--Általános Orvostudományi Kar; Kolozsvari, Rudolf; Maros, Tamás; Általános Orvostudományi Kar::Kardiológiai Intézet; Általános Orvostudományi Kar::Kardiológiai Intézet::Szívsebészeti TanszékThe postoperative occlusion of surgical venous or arterial grafts following coronary artery bypass graft (CABG) surgery is a constant and unsolved problem that has a negative impact on clinical outcomes. Maintaining graft patency is essential to achieve desired effects of CABG surgery. Although CABG is common and reliable revascularization procedure, along with percutaneous coronary intervention (PCI), the management of grafts (prevention of graft occlusion) remains one of the biggest challenges in this field. This review will focus on different factors that influence the development of graft occlusion. Initially, historical aspects of CABG and the pathogenesis of graft occlusion will be reviewed, especially emphasizing the role of inflammatory responses and factors associated with venous graft remodeling. The clinical results and conclusions of the CABG database of the Department of Cardiology, University of Debrecen is also discussed in detail. Finally, the potential therapeutic options will be reviewed together with graft occlusions prevention to improve clinical outcomes after CABG procedure.